ATE412418T1 - Zusammensetzungen zur erhöhung der zahl antigen präsentierender zellen und der antitumoralen antwort in menschlichen patienten - Google Patents

Zusammensetzungen zur erhöhung der zahl antigen präsentierender zellen und der antitumoralen antwort in menschlichen patienten

Info

Publication number
ATE412418T1
ATE412418T1 AT99916354T AT99916354T ATE412418T1 AT E412418 T1 ATE412418 T1 AT E412418T1 AT 99916354 T AT99916354 T AT 99916354T AT 99916354 T AT99916354 T AT 99916354T AT E412418 T1 ATE412418 T1 AT E412418T1
Authority
AT
Austria
Prior art keywords
csf
present
antigen
apc
tumor
Prior art date
Application number
AT99916354T
Other languages
English (en)
Inventor
Michael Roth
Robert Figlin
Sylvia Kiertscher
Barbara Gitlitz
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE412418T1 publication Critical patent/ATE412418T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99916354T 1998-04-02 1999-04-02 Zusammensetzungen zur erhöhung der zahl antigen präsentierender zellen und der antitumoralen antwort in menschlichen patienten ATE412418T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8051298P 1998-04-02 1998-04-02
US11578899P 1999-01-13 1999-01-13

Publications (1)

Publication Number Publication Date
ATE412418T1 true ATE412418T1 (de) 2008-11-15

Family

ID=26763616

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99916354T ATE412418T1 (de) 1998-04-02 1999-04-02 Zusammensetzungen zur erhöhung der zahl antigen präsentierender zellen und der antitumoralen antwort in menschlichen patienten

Country Status (7)

Country Link
EP (1) EP1076564B1 (de)
JP (1) JP2002510642A (de)
AT (1) ATE412418T1 (de)
AU (1) AU748850B2 (de)
CA (1) CA2326739A1 (de)
DE (1) DE69939821D1 (de)
WO (1) WO1999051257A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001279775A1 (en) * 2000-07-28 2002-02-13 Liponova Gmbh Medicament for the immunotherapy of malignant tumours
US20020094323A1 (en) 2000-10-12 2002-07-18 Kristoffer Hellstrand Methods and compositions for promoting the maturation of monocytes
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
JP6430949B2 (ja) * 2012-10-23 2018-11-28 エモリー ユニバーシティ Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
WO2017175200A1 (en) 2016-04-08 2017-10-12 The Regents Of The University Of California Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277368B1 (en) * 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
EP0930892A1 (de) * 1996-10-16 1999-07-28 The Johns Hopkins University Zytokin-erhoehte immuntherapie gegen gehirntumore

Also Published As

Publication number Publication date
DE69939821D1 (de) 2008-12-11
EP1076564A1 (de) 2001-02-21
AU3469599A (en) 1999-10-25
WO1999051257A1 (en) 1999-10-14
EP1076564B1 (de) 2008-10-29
AU748850B2 (en) 2002-06-13
EP1076564A4 (de) 2005-02-23
JP2002510642A (ja) 2002-04-09
CA2326739A1 (en) 1999-10-14

Similar Documents

Publication Publication Date Title
ES2298418T3 (es) Procedimiento para la preparacion de una libreria de arnm de antigenos tumorales.
Shimizu et al. Enhancement of tumor lysate-and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein
CA2727388C (en) Telomerase-derived peptides for use in treatment of cancer
AR004445A1 (es) Una composicion inmunogenica, una dosis unitaria, un metodo para producir la composicion, un kit para producir la composicion, una poblacion de celulas,uso de dicha poblacion celular y una preparacion combinada
Lichtor et al. Prolonged survival of mice with glioma injected intracerebrally with double cytokine—secreting cells
Crittenden et al. Intratumoral immunotherapy: using the tumour against itself
ATE276758T1 (de) Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
HUP0303125A2 (hu) Bcl-2 rendellenességek kezelésére szolgáló eljárások bcl-2 antiszenz oligomerekkel
HUP0103598A2 (hu) Készítmények és eljárások WT1-specifikus immunterápiás alkalmazásra
WO2005079867A3 (en) Alpha-emitting hydroxyapatite particles
Dalgleish Cancer vaccines
WO2004104591A3 (en) Improvements to gamma delta t cell-mediated therapy
DE69939821D1 (de) Zusammensetzungen zur erhöhung der zahl antigen präsentierender zellen und der antitumoralen antwort in menschlichen patienten
BR0015597A (pt) Uso de anticorpos como vacinas
WO2001029192A3 (en) Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses
Loducca et al. Intraosseous rhabdomyosarcoma of the mandible: a case report
Suntharalingam et al. The use of concurrent chemotherapy with high-dose radiation before surgical resection in patients presenting with apical sulcus tumors.
DK1735013T3 (da) Alfa- og beta-udsendende hydroxyapatitpartikler
Schlund et al. Zygomatic swing approach to the infratemporal fossa
Pandey et al. Cancer vaccines: a step towards prevention and treatment of cancer
Schroten-Loef et al. A prostate cancer vaccine comprising whole cells secreting IL-7, effective against subcutaneous challenge, requires local GM-CSF for intra-prostatic efficacy
MD2355F1 (en) Method of preimplanting preparation
WO2003103706A3 (en) Immunogenic compositions comprising a xenogenic prostate protein p501s
RU2203683C1 (ru) Способ иммунотерапии костно-мозговыми дендритными клетками больных солидными опухолями
Kausch et al. Immune gene therapy in urology

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties